WO2009109631A9 - Cellule de fermentation de sucre pentose - Google Patents

Cellule de fermentation de sucre pentose Download PDF

Info

Publication number
WO2009109631A9
WO2009109631A9 PCT/EP2009/052621 EP2009052621W WO2009109631A9 WO 2009109631 A9 WO2009109631 A9 WO 2009109631A9 EP 2009052621 W EP2009052621 W EP 2009052621W WO 2009109631 A9 WO2009109631 A9 WO 2009109631A9
Authority
WO
WIPO (PCT)
Prior art keywords
cell
xylose
cell according
gene
acid
Prior art date
Application number
PCT/EP2009/052621
Other languages
English (en)
Other versions
WO2009109631A1 (fr
Inventor
Paul Klaassen
Van Der Jan Metske Laan
Bianca Elisbeth Maria Gielesen
Van Gijsberdina Pieternella Suylekom
Original Assignee
Dsm Ip Assets B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V. filed Critical Dsm Ip Assets B.V.
Publication of WO2009109631A1 publication Critical patent/WO2009109631A1/fr
Publication of WO2009109631A9 publication Critical patent/WO2009109631A9/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C12N9/92—Glucose isomerase (5.3.1.5; 5.3.1.9; 5.3.1.18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P7/00—Preparation of oxygen-containing organic compounds
    • C12P7/02—Preparation of oxygen-containing organic compounds containing a hydroxy group
    • C12P7/04—Preparation of oxygen-containing organic compounds containing a hydroxy group acyclic
    • C12P7/06—Ethanol, i.e. non-beverage
    • C12P7/08—Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate
    • C12P7/10—Ethanol, i.e. non-beverage produced as by-product or from waste or cellulosic material substrate substrate containing cellulosic material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
    • Y02E50/00—Technologies for the production of fuel of non-fossil origin
    • Y02E50/10—Biofuels, e.g. bio-diesel

Definitions

  • the present invention relates to a cell which is capable of isomerising xylose to xylulose.
  • the invention also relates to a process in which such cells are used for the production of a fermentation product, such as ethanol.
  • biomass-derived ethanol may be produced by the fermentation of hexose sugars obtained from many different sources
  • substrates typically used for commercial scale production of fuel alcohol, such as cane sugar and corn starch are expensive. Increases in the production of fuel ethanol will therefore require the use of lower-cost feedstocks.
  • a cell that is capable of fermentation, such as alcoholic fermentation, and of using xylose as a carbon source.
  • a cell comprises a nucleotide sequence encoding a xylose isomerase, wherein the amino acid sequence of the xylose isomerase has at least about 70% sequence identity to the amino acid sequence set out in SEQ ID NO: 3 and wherein the nucleotide sequence is heterologous to the host.
  • Such a cell produces a higher amount of ethanol when using xylose as a carbon source as compared to the wild type filamentous fungus.
  • the invention also provides: - a process for producing a fermentation product which process comprises fermenting a medium containing a source of xylose with a cell of the invention such that the cell ferments xylose to the fermentation product; a process for producing a fermentation product which process comprises fermenting a medium containing at least a source of xylose and a source of L- arabinose with a cell as defined of the invention which is also capable of utilizing L-arabinose such that the cell ferments xylose and L-arabinose to the fermentation product; and a process for producing a fermentation product which process comprises fermenting a medium containing at least a source of xylose and a source of L- arabinose with a cell of the invention and a cell able to use L-arabinose, whereby each cell ferments xylose and/or arabinose to the fermentation product.
  • the invention further provides the use of a cell of the invention in a process for the production of a fermentation product.
  • Figure 1 sets out the plasmid map of pYISIT4-XKS1-xylA (Thma CpO) encoding xylose isomerase from Thermotoga maritima MSB8 for expression in Saccharomyces cerevisiae.
  • CpO denotes codon pair optimized.
  • Figure 2 Physical map of plasmid pPWT080
  • Figure 3 Physical map of the wild-type GRE3-locus (panel a) and a one copy integration of PWT080 in the GRE3-locus (panel b, showing where the primers bind and panel c, showing where the RKH-probe binds)
  • Figure 4 Autoradiogram showing the correct integration of one copy of the plasmid pPWT080 in CEN.PK1 13-7D
  • Lane i CEN.PK1 13-7D; lane 2: BIE104F1 ; lane 3: BIE104P1 Panel b:Ps/ ⁇ -digestion of chromosomal DNA preparations, hybridized with the RKM -probe.
  • Figure 5 Physical map of the GRE3-locus, where the coding region of the
  • GRE3-gene was replaced by the integration of the PPP-genes TAL1, TKL1, RKH and RPE1.
  • Panel a shows the where the primers of SEQ ID 5 and 6 bind
  • panel b shows where the RKI1-probe binds.
  • Figure 7 physical map of plasmid pPWT007
  • Figure 8 physical map of plasmid pPWT049
  • Figure 9 Physical map of the wild-type S/74-locus (panel a) and a one copy integration of pPWT049 in the S/74-locus (panel b, showing where the primers bind)
  • SEQ ID NO: 1 sets out the wild-type xylose isomerase sequence from Thermotoga maritima MSB8. Genbank accession no. NC_000853.
  • SEQ ID NO: 2 sets out a codon optimized sequence derived from SEQ ID NO: 1. -A-
  • SEQ ID NO: 3 sets out the amino acid sequence of xylose isomerase from Thermotoga maritima MSB8.
  • SEQ ID NO: 4 sets out the sequence of plasmid pPWT080.
  • SEQ ID NO: 5 sets out a forward primer.
  • SEQ ID NO: 6 sets out a reverse primer.
  • SEQ ID NO: 7 sets out a multifunctional forward primer for diagnostic PCR.
  • SEQ ID NO: 8 sets out a multifunctional reverse primer for diagnostic PCR.
  • SEQ ID NO: 9 sets out a forward primer RKM -probe.
  • SEQ ID NO: 10 sets out a reverse primer RKM -probe.
  • SEQ ID NO: 11 sets out a forward primer kanMX-cassette.
  • SEQ ID NO: 12 sets out a reverse primer kanMX-cassette.
  • SEQ ID NO: 13 sets out the sequence of forward primer.
  • SEQ ID NO: 14 sets out the sequence of reverse primer.
  • SEQ ID NO: 15 sets out the sequence of forward multifunctional primer for diagnostic PCR.
  • SEQ ID NO: 16 sets out the sequence of reverse multifunctional primer for diagnostic PCR.
  • the invention relates to a cell which comprises a nucleotide sequence encoding a xylose isomerase, wherein the amino acid sequence of the xylose isomerase has at least about 70% identity to the amino acid sequence set out in SEQ ID NO: 3 and wherein the nucleotide sequence is heterologous to the host.
  • the presence of the nucleotide sequence encoding a xylose isomerase confers on the cell the ability to isomerise xylose to xylulose.
  • a "xylose isomerase” (EC 5.3.1.5) is herein defined as an enzyme that catalyses the direct isomerisation of D-xylose into D-xylulose and/or vice versa.
  • the enzyme is also known as a D-xylose ketoisomerase.
  • a xylose isomerase herein may also be capable of catalysing the conversion between D-glucose and D-fructose (and accordingly may therefore be referred to as a glucose isomerase).
  • a xylose isomerase herein may require a bivalent cation, such as magnesium, manganese or cobalt as a cofactor. Accordingly, a cell of the invention is capable of isomerising xylose to xylulose.
  • a cell of the invention isomerises xylose into xylulose by the direct isomerisation of xylose to xylulose.
  • xylose is isomerised into xylulose in a single reaction catalysed by a xylose isomerase, as opposed to two step conversion of xylose into xylulose via a xylitol intermediate as catalysed by xylose reductase and xylitol dehydrogenase, respectively.
  • a unit (U) of xylose isomerase activity may herein be defined as the amount of enzyme producing 1 nmol of xylulose per minute, under conditions as described by Kuyper et al. (2003, FEMS Yeast Res. 4: 69-78).
  • the cell of the invention is defined with reference to a xylose isomerase having the amino acid sequence of SEQ ID NO: 3 or a sequence having at least about 70% sequence identity thereto.
  • a cell of the invention may be defined with reference to a xylose isomerase be a nucleotide sequence which encoding such an amino acid sequence.
  • SEQ ID NO: 3 sets out the amino acid sequence of xylose isomerase from
  • a cell of the invention comprises a nucleotide sequence encoding a xylose isomerase having the amino acid of SEQ ID NO: 3 or one which has at least about 70% sequence identity thereto.
  • a cell according to the present invention is a cell comprising a nucleotide sequence encoding a xylose isomerase having a sequence which has at least about 75%, preferably at least about 80%, at least about 85%, at least about 90%, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99% or at least 75%, at least 80%, at least 85%, at least 90%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity with the amino acid sequence of SEQ ID NO:3.
  • a cell according according to the present invention may comprise a nucleotide sequence encoding a xylose isomerase having a sequence which has at least about 50%, at least about 55%, at least about 60% or at least about 70% sequence identity with the amino acid sequence set out in SEQ ID NO: 3.
  • Sequence identity is herein defined as a relationship between two or more amino acid (polypeptide or protein) sequences or two or more nucleic acid (polynucleotide) sequences, as determined by comparing the sequences. Usually, sequence identities or similarities are compared, typically over the whole length of the sequences compared. However, sequences may be compared over shorter comparison windows. In the art, “identity” also means the degree of sequence relatedness between amino acid or nucleic acid sequences, as the case may be, as determined by the match between strings of such sequences.
  • Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include e.g. the BestFit, BLASTP, BLASTN, and FASTA (Altschul, S. F. et al., J. MoI. Biol. 215:403-410 (1990), publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894). Preferred parameters for amino acid sequences comparison using BLASTP are gap open 11.0, gap extend 1 , Blosum 62 matrix. Preferred parameters for nucleic acid sequences comparison using BLASTP are gap open 1 1.0, gap extend 1 , DNA full matrix (DNA identity matrix).
  • the skilled person may also take into account so-called “conservative" amino acid substitutions, as will be clear to the skilled person.
  • Conservative amino acid substitutions refer to the interchangeability of residues having similar side chains.
  • a group of amino acids having aliphatic side chains is glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains is serine and threonine; a group of amino acids having amide-containing side chains is asparagine and glutamine; a group of amino acids having aromatic side chains is phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains is lysine, arginine, and histidine; and a group of amino acids having sulphur-containing side chains is cysteine and methionine.
  • Preferred conservative amino acids substitution groups are: valine-leucine- isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine- valine, and asparagine- glutamine.
  • Substitutional variants of the amino acid sequence disclosed herein are those in which at least one residue in the disclosed sequences has been removed and a different residue inserted in its place.
  • the amino acid change is conservative.
  • Preferred conservative substitutions for each of the naturally occurring amino acids are as follows: Ala to ser; Arg to lys; Asn to gin or his; Asp to glu; Cys to ser or ala; GIn to asn; GIu to asp; GIy to pro; His to asn or gin; He to leu or val; Leu to ile or val; Lys to arg; gin or glu; Met to leu or ile; Phe to met, leu or tyr; Ser to thr; Thr to ser; Trp to tyr; Tyr to trp or phe; and, VaI to ile or leu.
  • a nucleotide sequence encoding an enzyme which catalyses the conversion of xylose to xylulose according to the invention may also be defined by its capability to hybridise with the nucleotide sequences encoding the enzyme having the sequence set out in SEQ ID NO: 3 or a sequence having at least about 70% sequence identity therewith, under moderate, or preferably under stringent hybridisation conditions.
  • nucleotide sequences hybridize with the reverse complement of the nucleotide sequences which encode the enzyme having the sequence set out in SEQ ID NO: 3 or a sequence having at least about 70% sequence identity therewith, for examples sequences which hybridize with the reverse complement of SEQ ID NOs: 1 or 2.
  • Stringent hybridisation conditions are herein defined as conditions that allow a nucleic acid sequence of at least about 25, preferably about 50 nucleotides, 75 or 100 and most preferably of about 200 or more nucleotides, to hybridise at a temperature of about 65°C in a solution comprising about 1 M salt, preferably 6 x SSC (sodium chloride, sodium citrate) or any other solution having a comparable ionic strength, and washing at 65°C in a solution comprising about 0.1 M salt, or less, preferably 0.2 x SSC or any other solution having a comparable ionic strength.
  • the hybridisation is performed overnight, i.e. at least for 10 hours and preferably washing is performed for at least one hour with at least two changes of the washing solution.
  • Moderate conditions are herein defined as conditions that allow a nucleic acid sequences of at least 50 nucleotides, preferably of about 200 or more nucleotides, to hybridise at a temperature of about 45 0 C in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength, and washing at room temperature in a solution comprising about 1 M salt, preferably 6 x SSC or any other solution having a comparable ionic strength.
  • the hybridisation is performed overnight, i.e. at least for 10 hours, and preferably washing is performed for at least one hour with at least two changes of the washing solution.
  • These conditions will usually allow the specific hybridisation of sequences having up to 50% sequence identity.
  • the person skilled in the art will be able to modify these hybridisation conditions in order to specifically identify sequences varying in identity between 50% and 90%.
  • the corresponding encoding nucleotide sequence may be adapted to optimise its codon usage to that of the chosen yeast cell.
  • codon optimisation Several methods for codon optimisation are known in the art.
  • a preferred method to optimise codon usage of the nucleotide sequences to that of the yeast is a codon pair optimization technology as disclosed in WO2006/077258 and/or WO2008/000632.
  • WO2008/000632 addresses codon-pair optimization.
  • Codon-pair optimisation is a method wherein the nucleotide sequences encoding a polypeptide are modified with respect to their codon-usage, in particular the codon-pairs that are used, to obtain improved expression of the nucleotide sequence encoding the polypeptide and/or improved production of the encoded polypeptide. Codon pairs are defined as a set of two subsequent triplets (codons) in a coding sequence.
  • CAI Codon Adaptation Index
  • the index uses a reference set of highly expressed genes from a species to assess the relative merits of each codon, and a score for a gene is calculated from the frequency of use of all codons in that gene.
  • the index assesses the extent to which selection has been effective in moulding the pattern of codon usage. In that respect it is useful for predicting the level of expression of a gene, for assessing the adaptation of viral genes to their hosts, and for making comparisons of codon usage in different organisms.
  • the index may also give an approximate indication of the likely success of heterologous gene expression.
  • the CAI is 0.6 or more, 0.7 or more, 0.8 or more, 0.85 or more, 0.87 or more 0.90 or more, 0.95 or more, or about 1.0.
  • the xylose isomerase is typically heterologous to the cell. That is to say, the xylose isomerase has a sequence which does not naturally occur in the cell in question as part of the organism, cell, genome DNA or RNA sequence in which it is present. That is to say, the xylose isomerase is exogenous to the cell or does not occur naturally in the cell. Accordingly, a nucleotide sequence encoding a xylose isomerase is typically expressed or is capable of being expressed in active form in the transformed host cell.
  • a cell of the invention is thus a cell that comprises, i.e. has been transformed with, a nucleic acid construct comprising the nucleotide sequence encoding the xylose isomerase as defined above.
  • the nucleic acid construct comprising the xylose isomerase coding sequence preferably is capable of expression of the xylose isomerase in the host cell.
  • the cell may comprise (and express) one or more of the nucleotide sequences encoding ribulose-5-phosphate isomerase, ribulose-5-phosphate epimerase, transketolase or transaldolase. These nucleotide sequences may be derived from Pichia, such as Pichia stipitus, or a related sequence, such as a codon-optimized sequence.
  • the expression of the one or more sequences is such that the cell has an increased flux through the pentose phosphate pathway (PPP).
  • PPP pentose phosphate pathway
  • Increased flux through the PPP in this context indicates that a cell of the invention has increased flux through the PPP as compared to a cell which is identical to a cell of the invention except that it does not comprise one or more of the said nucleotide sequences encoding a component of the PPP.
  • a cell of the invention is a recombinant cell. That is to say, a cell of the invention comprises, or is transformed with or is genetically modified with a nucleotide sequence that does not naturally occur in the cell in question.
  • the vector design in the case of stable integration is thus, that upon loss of the selection marker genes (which also occurs by intramolecular, homologous recombination) that looping out of the integrated construct is no longer possible.
  • the genes are thus stably integrated.
  • Stable integration is herein defined as integration into the genome, wherein looping out of the integrated construct is no longer possible.
  • selection markers are absent.
  • the nucleic acid construct may be a plasmid, for instance a low copy plasmid or a high copy plasmid.
  • the cell according to the present invention may comprise a single or multiple copies of the nucleotide sequence encoding a xylose isomerase, for instance by multiple copies of a nucleotide construct or by use of construct which has multiple copies of the xylose isomerase sequence.
  • the nucleic acid construct may be maintained episomally and thus comprise a sequence for autonomous replication, such as an autosomal replication sequence sequence.
  • a suitable episomal nucleic acid construct may e.g. be based on the yeast 2 ⁇ or pKD1 plasmids (Gleer et al., 1991 , Biotechnology 9: 968-975), or the AMA plasmids (Fierro et al., 1995, Curr Genet. 29:482-489).
  • each nucleic acid construct may be integrated in one or more copies into the genome of the cell. Integration into the cell's genome may occur at random by non-homologous recombination but preferably, the nucleic acid construct may be integrated into the cell's genome by homologous recombination as is well known in the art (see e.g. WO90/14423, EP-A-0481008, EP-A-0635 574 and US 6,265,186).
  • the xylose isomerase encoding sequence will be operably linked to one or more nucleic acid sequences, capable of providing for or aiding the transcription and/or translation of the xylose isomerase sequence.
  • promoter refers to a juxtaposition wherein the components described are in a relationship permitting them to function in their intended manner.
  • a promoter or enhancer is operably linked to a coding sequence the said promoter or enhancer affects the transcription of the coding sequence.
  • promoter refers to a nucleic acid fragment that functions to control the transcription of one or more genes, located upstream with respect to the direction of transcription of the transcription initiation site of the gene, and is structurally identified by the presence of a binding site for DNA-dependent RNA polymerase, transcription initiation sites and any other DNA sequences known to one of skilled in the art.
  • a "constitutive" promoter is a promoter that is active under most environmental and developmental conditions.
  • An “inducible” promoter is a promoter that is active under environmental or developmental regulation.
  • the promoter that could be used to achieve the expression of a nucleotide sequence coding for an enzyme according to the present invention may be not native to the nucleotide sequence coding for the enzyme to be expressed, i.e. a promoter that is heterologous to the nucleotide sequence (coding sequence) to which it is operably linked.
  • the promoter may, however, be homologous, i.e. endogenous, to the host cell.
  • Suitable promoters in this context include both constitutive and inducible natural promoters as well as engineered promoters, which are well known to the person skilled in the art.
  • Suitable promoters in eukaryotic host cells may be GALl, GAL10, or GAL1, CYC1, HIS3, ADH1, PGL, PH05, GAPDH, ADC1, TRP1, URA3, LEU2, EN01, TPH, and A0X1.
  • Other suitable promoters include PDC1, GPD1, PGK1, TEF1, and TDH3.
  • the 3 '-end of the nucleotide acid sequence encoding xylose isomerase preferably is operably linked to a transcription terminator sequence.
  • the terminator sequence is operable in a host cell of choice, such as e.g. the yeast species of choice.
  • the choice of the terminator is not critical; it may e.g. be from any yeast gene, although terminators may sometimes work if from a non- yeast, eukaryotic, gene.
  • a nucleotide sequence encoding the xylose isomerase comprises a terminator.
  • such terminators are combined with mutations that prevent nonsense mediated mRNA decay in the host cell of the invention (see for example: Shirley et al., 2002, Genetics 161 :1465-1482).
  • the transcription termination sequence further preferably comprises a polyadenylation signal.
  • a selectable marker may be present in a nucleic acid construct suitable for use in the invention.
  • the term "marker” refers to a gene encoding a trait or a phenotype which permits the selection of, or the screening for, a host cell containing the marker.
  • the marker gene may be an antibiotic resistance gene whereby the appropriate antibiotic can be used to select for transformed cells from among cells that are not transformed.
  • suitable antibiotic resistance markers include e.g. dihydrofolate reductase, hygromycin-B-phosphotransferase, 3'-O- phosphotransferase Il (kanamycin, neomycin and G418 resistance).
  • antibiotic resistance markers may be most convenient for the transformation of polyploid host cells, preferably however, non- antibiotic resistance markers are used, such as auxotrophic markers (URA3, TRPI, LEU2) or the S. pombe TPI gene (described by Russell P R, 1985, Gene 40: 125-130).
  • the host cells transformed with the nucleic acid constructs are marker gene free. Methods for constructing recombinant marker gene free microbial host cells are disclosed in EP-A-O 635 574 and are based on the use of bidirectional markers such as the A. nidulans amdS (acetamidase) gene or the yeast URA3 and LYS2 genes.
  • a screenable marker such as Green Fluorescent Protein, lacL, luciferase, chloramphenicol acetyltransferase, beta-glucuronidase may be incorporated into the nucleic acid constructs of the invention allowing to screen for transformed cells.
  • a screenable marker such as Green Fluorescent Protein, lacL, luciferase, chloramphenicol acetyltransferase, beta-glucuronidase may be incorporated into the nucleic acid constructs of the invention allowing to screen for transformed cells.
  • further elements that may be present in the nucleic acid constructs suitable for use in the invention include, but are not limited to, one or more leader sequences, enhancers, integration factors, and/or reporter genes, intron sequences, centromers, telomers and/or matrix attachment (MAR) sequences.
  • the nucleic acid constructs of the invention may further comprise a sequence for autonomous replication, such as an ARS sequence.
  • the xylose isomerase is expressed in the cytosol.
  • Cytosolic expression may be achieved by deletion or modification of a mitochondrial or peroxisomal targeting signal.
  • a cell of the invention may be any suitable cell, such as a prokaryotic cell, such as a bacterium, or a eukaryotic cell.
  • the cell will be a eukaryotic cell, for example a yeast or a filamentous fungus.
  • Yeasts are herein defined as eukaryotic microorganisms and include all species of the subdivision Eumycotina (Alexopoulos, C. J. ,1962, In : Introductory Mycology, John Wiley & Sons, Inc. , New York) that predominantly grow in unicellular form.
  • Eumycotina Alexopoulos, C. J. ,1962, In : Introductory Mycology, John Wiley & Sons, Inc. , New York
  • Yeasts may either grow by budding of a unicellular thallus or may grow by fission of the organism.
  • a preferred yeast as a cell of the invention may belong to the genera Saccharomyces, Kluyveromyces, Candida, Pichia, Schizosaccharomyces, Hansenula, Kloeckera, Schwanniomyces or Yarrowia.
  • the yeast is one capable of anaerobic fermentation, more preferably one capable of anaerobic alcoholic fermentation.
  • Filamentous fungi are herein defined as eukaryotic microorganisms that include all filamentous forms of the subdivision Eumycotina. These fungi are characterized by a vegetative mycelium composed of chitin, cellulose, and other complex polysaccharides.
  • filamentous fungi of the suitable for use as a cell of the present invention are morphologically, physiologically, and genetically distinct from yeasts.
  • Filamentous fungal cells may be advantageously used since most fungi do not require sterile conditions for propagation and are insensitive to bacteriophage infections. Vegetative growth by filamentous fungi is by hyphal elongation and carbon catabolism of most filamentous fungi is obligately aerobic.
  • Preferred filamentous fungi as a host cell of the invention may belong to the genus Aspergillus, Trichoderma, Humicola, Acremoniurra, Fusarium or Penicillium. More preferably, the filamentous fungal cell may be a Aspergillus niger, Aspergillus oryzae, a Penicillium chrysogenum, or Rhizopus oryzae cell.
  • yeasts of the genus Saccharomyces as ethanol producer. This is due to the many attractive features of Saccharomyces species for industrial processes, i. e. , a high acid-, ethanol-and osmo- tolerance, capability of anaerobic growth, and of course its high alcoholic fermentative capacity.
  • Preferred yeast species as host cells include S. cerevisiae, S. bulderi, S. barnetti, S. exiguus, S. uvarum, S. diastaticus, K. lactis, K. marxianus or K fragilis.
  • a cell of the invention may be able to convert plant biomass, celluloses, hemicelluloses, pectins, rhamnose, galactose, fucose, maltose, maltodextrines, ribose, ribulose, or starch, starch derivatives, sucrose, lactose and glycerol, for example into fermentable sugars.
  • a cell of the invention may express one or more enzymes such as a cellulase (an endocellulase or an exocellulase), a hemicellulase (an endo- or exo-xylanase or arabinase) necessary for the conversion of cellulose into glucose monomers and hemicellulose into xylose and arabinose monomers, a pectinase able to convert pectins into glucuronic acid and galacturonic acid or an amylase to convert starch into glucose monomers.
  • a cell of the invention is preferably is a host capable of active or passive xylose transport into the cell.
  • a cell of the invention is capable of active glycolysis; and/or shows flux through the pentose phosphate pathway; and/or displays xylulose kinase activity so that the xylulose isomerised from xylose may be metabolised to pyruvate.
  • the cell further preferably comprises those enzymatic activities required for conversion of pyruvate to a desired fermentation product, such as ethanol, butanol, lactic acid, 3 -hydroxy- propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, fumaric acid, malic acid, itaconic acid, an amino acid, 1 ,3- propane-diol, ethylene, glycerol, a ⁇ -lactam antibiotic or a cephalosporin.
  • a desired fermentation product such as ethanol, butanol, lactic acid, 3 -hydroxy- propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, fumaric acid, malic acid, itaconic acid, an amino acid, 1 ,3- propane-diol, ethylene, glycerol, a ⁇ -lactam antibiotic or a cephalosporin.
  • a preferred cell of the invention is a cell that is naturally capable of alcoholic fermentation, preferably, anaerobic alcoholic fermentation.
  • a cell of the invention preferably has a high tolerance to ethanol, a high tolerance to low pH (i.e. capable of growth at a pH lower than about 5, about 4, about 3, or about 2.5) and towards organic acids like lactic acid, acetic acid or formic acid and/or sugar degradation products such as furfural and hydroxy- methylfurfural and/or a high tolerance to elevated temperatures.
  • any of the above characteristics or activities of a cell of the invention may be naturally present in the cell or may be introduced or modified by genetic modification.
  • the nucleotide sequence encoding a xylose isomerase is typically expressed or is capable of being expressed in active form in the transformed host cell.
  • expression of the nucleotide sequence in the host cell produces an active xylose isomerase, typically with a specific activity of at least about 10 U xylose isomerase activity per mg protein at about 3O 0 C, preferably at least about 20, at least about 25, at least about 30, at least about 50, at least about 100, at least about 200, at least about 300, at least about 500, at least about 750 or at least about 1000 U per mg at about 3O 0 C.
  • the specific activity of the xylose isomerase expressed in the transformed host cell is herein defined as the amount of xylose isomerase activity units per mg protein of cell free lysate of the host cell, e.g. a yeast cell free lysate. Determination of the xylose isomerase activity, amount of protein and preparation of the cell free lysate are as described herein.
  • expression of the nucleotide sequence encoding the xylose isomerase in the host cell produces a xylose isomerase with a K m for xylose that is less than 50, 40, 30 or 25 mM, more preferably, the K m for xylose is about 20 mM or less.
  • a cell of the invention may comprise one ore more genetic modifications that increases the flux of the pentose phosphate pathway.
  • the genetic modification(s) may lead to an increased flux through the non-oxidative part pentose phosphate pathway.
  • a genetic modification that causes an increased flux of the non- oxidative part of the pentose phosphate pathway is herein understood to mean a modification that increases the flux by at least a factor of about 1.1 , about 1.2, about 1.5, about 2, about 5, about 10 or about 20 as compared to the flux in a strain which is genetically identical except for the genetic modification causing the increased flux.
  • the flux of the non-oxidative part of the pentose phosphate pathway may be measured by growing the modified host on xylose as sole carbon source, determining the specific xylose consumption rate and subtracting the specific xylitol production rate from the specific xylose consumption rate, if any xylitol is produced.
  • the flux of the non-oxidative part of the pentose phosphate pathway is proportional with the growth rate on xylose as sole carbon source, preferably with the anaerobic growth rate on xylose as sole carbon source. There is a linear relation between the growth rate on xylose as sole carbon source ( ⁇ max ) and the flux of the non-oxidative part of the pentose phosphate pathway.
  • One or more genetic modifications that increase the flux of the pentose phosphate pathway may be introduced in the host cell in various ways. These including e.g. achieving higher steady state activity levels of xylulose kinase and/or one or more of the enzymes of the non-oxidative part pentose phosphate pathway and/or a reduced steady state level of unspecific aldose reductase activity. These changes in steady state activity levels may be effected by selection of mutants (spontaneous or induced by chemicals or radiation) and/or by recombinant DNA technology e.g. by overexpression or inactivation, respectively, of genes encoding the enzymes or factors regulating these genes.
  • the genetic modification comprises overexpression of at least one enzyme of the (non-oxidative part) pentose phosphate pathway.
  • the enzyme is selected from the group consisting of the enzymes encoding for ribulose- 5- phosphate isomerase, ribulose-5-phosphate epimerase, transketolase and transaldolase.
  • Various combinations of enzymes of the (non-oxidative part) pentose phosphate pathway may be overexpressed. E.g.
  • the enzymes that are overexpressed may be at least the enzymes ribulose-5-phosphate isomerase and ribulose-5- phosphate epimerase; or at least the enzymes ribulose-5-phosphate isomerase and transketolase; or at least the enzymes ribulose-5-phosphate isomerase and transaldolase; or at least the enzymes ribulose-5-phosphate epimerase and transketolase; or at least the enzymes ribulose-5- phosphate epimerase and transaldolase; or at least the enzymes transketolase and transaldolase; or at least the enzymes ribulose-5-phosphate epimerase, transketolase and transaldolase; or at least the enzymes ribulose-5-phosphate isomerase, transketolase and transaldolase; or at least the enzymes ribulose-5-phosphate isomerase, transketolase and transaldolase; or at least the enzymes ribulose-5-phosphate is
  • each of the enzymes ribulose-5-phosphate isomerase, ribulose-5-phosphate epimerase, transketolase and transaldolase are overexpressed in the host cell. More preferred is a host cell in which the genetic modification comprises at least overexpression of both the enzymes transketolase and transaldolase as such a host cell is already capable of anaerobic growth on xylose. In fact, under some conditions host cells overexpressing only the transketolase and the transaldolase already have the same anaerobic growth rate on xylose as do host cells that overexpress all four of the enzymes, i.e.
  • ribulose-5-phosphate isomerase ribulose-5-phosphate epimerase
  • transketolase transaldolase
  • host cells overexpressing both of the enzymes ribulose-5- phosphate isomerase and ribulose-5- phosphate epimerase are preferred over host cells overexpressing only the isomerase or only the epimerase as overexpression of only one of these enzymes may produce metabolic imbalances.
  • ribulose 5-phosphate epimerase (5.1.3.1 ) is herein defined as an enzyme that catalyses the epimerisation of D-xylulose 5-phosphate into D-ribulose 5- phosphate and vice versa.
  • the enzyme is also known as phosphoribulose epimerase; erythrose-4-phosphate isomerase; phosphoketopentose 3-epimerase; xylulose phosphate 3-epimerase; phosphoketopentose epimerase; ribulose 5-phosphate 3- epimerase; D-ribulose phosphate-3-epimerase; D-ribulose 5-phosphate epimerase; D- ribulose-5-P 3-epimerase; D-xylulose-5-phosphate 3-epimerase; pentose-5-phosphate 3-epimerase; or D-ribulose-5-phosphate 3-epimerase.
  • a ribulose 5-phosphate epimerase may be further defined by its amino acid sequence.
  • a ribulose 5- phosphate epimerase may be defined by a nucleotide sequence encoding the enzyme as well as by a nucleotide sequence hybridising to a reference nucleotide sequence encoding a ribulose 5-phosphate epimerase.
  • the nucleotide sequence encoding for ribulose 5-phosphate epimerase from Saccharomyces cerevisiae is herein designated RPE1.
  • ribulose 5-phosphate isomerase (EC 5.3.1.6) is herein defined as an enzyme that catalyses direct isomerisation of D-ribose 5-phosphate into D-ribulose 5-phosphate and vice versa.
  • the enzyme is also known as phosphopentosisomerase; phosphoriboisomerase; ribose phosphate isomerase; 5-phosphoribose isomerase; D- ribose 5-phosphate isomerase; D-ribose-5-phosphate ketol-isomerase; or D-ribose-5- phosphate aldose-ketose-isomerase.
  • a ribulose 5-phosphate isomerase may be further defined by its amino acid sequence.
  • a ribulose 5-phosphate isomerase may be defined by a nucleotide sequence encoding the enzyme as well as by a nucleotide sequence hybridising to a reference nucleotide sequence encoding a ribulose 5- phosphate isomerase.
  • the nucleotide sequence encoding for ribulose 5-phosphate isomerase from Saccharomyces cerevisiae is herein designated RPH.
  • transketolase (EC 2.2.1.1 ) is herein defined as an enzyme that catalyses the reaction: D-ribose 5-phosphate + D-xylulose 5-phosphate ⁇ -> sedoheptulose 7-phosphate + D-glyceraldehyde 3-phosphate and vice versa.
  • the enzyme is also known as glycolaldehydetransferase or sedoheptulose-7-phosphate:D- glyceraldehyde-3-phosphate glycolaldehydetransferase.
  • a transketolase may be further defined by its amino acid.
  • transketolase may be defined by a nucleotide sequence encoding the enzyme as well as by a nucleotide sequence hybridising to a reference nucleotide sequence encoding a transketolase.
  • the nucleotide sequence encoding for transketolase from Saccharomyces cerevisiae is herein designated TKL1.
  • the enzyme "transaldolase” (EC 2.2.1.2) is herein defined as an enzyme that catalyses the reaction: sedoheptulose 7-phosphate + D-glyceraldehyde 3-phosphate ⁇ - > D-erythrose 4-phosphate + D-fructose 6-phosphate and vice versa.
  • the enzyme is also known as dihydroxyacetonetransferase; dihydroxyacetone synthase; formaldehyde transketolase; or sedoheptulose-7- phosphate :D-glyceraldehyde-3 -phosphate glyceronetransferase.
  • a transaldolase may be further defined by its amino acid sequence.
  • a transaldolase may be defined by a nucleotide sequence encoding the enzyme as well as by a nucleotide sequence hybridising to a reference nucleotide sequence encoding a transaldolase.
  • the nucleotide sequence encoding for transketolase from Saccharomyces cerevisiae is herein designated TAL1.
  • an enzyme may be overexpressed by increasing the copy number of the gene coding for the enzyme in the host cell, e.g. by integrating additional copies of the gene in the host cell's genome, by expressing the gene from an episomal multicopy expression vector or by introducing a episomal expression vector that comprises multiple copies of the gene.
  • overexpression of enzymes in the host cells of the invention may be achieved by using a promoter that is not native to the sequence coding for the enzyme to be overexpressed, i.e. a promoter that is heterologous to the coding sequence to which it is operably linked.
  • a promoter that is heterologous to the coding sequence to which it is operably linked
  • the promoter is also preferred that the promoter is homologous, i.e. endogenous to the host cell.
  • the heterologous promoter is capable of producing a higher steady state level of the transcript comprising the coding sequence (or is capable of producing more transcript molecules, i.e.
  • RNA molecules, per unit of time than is the promoter that is native to the coding sequence, preferably under conditions where xylose or xylose and glucose are available as carbon sources, more preferably as major carbon sources (i.e. more than 50% of the available carbon source consists of xylose or xylose and glucose), most preferably as sole carbon sources.
  • Suitable promoters in this context include both constitutive and inducible natural promoters as well as engineered promoters.
  • a preferred promoter for use in the present invention will in addition be insensitive to catabolite (glucose) repression and/or will preferably not require xylose for induction. Promotors having these characteristics are widely available and known to the skilled person. Suitable examples of such promoters include e.g.
  • promoters from glycolytic genes such as the phosphofructokinase (PFK), triose phosphate isomerase (TPI), glyceraldehyde-3 -phosphate dehydrogenase (GPD, TDH3 or GAPDH), pyruvate kinase (PYK), phosphoglycerate kinase (PGK) promoters from yeasts or filamentous fungi; more details about such promoters from yeast may be found in (WO 93/03159).
  • PFK phosphofructokinase
  • TPI triose phosphate isomerase
  • GPD glyceraldehyde-3 -phosphate dehydrogenase
  • PYK pyruvate kinase
  • PGK phosphoglycerate kinase
  • promoters are ribosomal protein encoding gene promoters, the lactase gene promoter (LAC4), alcohol dehydrogenase promoters (ADHI, ADH4, and the like), and the enolase promoter (ENO).
  • LAC4 lactase gene promoter
  • ADHI, ADH4, and the like alcohol dehydrogenase promoters
  • ENO enolase promoter
  • Other promoters, both constitutive and inducible, and enhancers or upstream activating sequences will be known to those of skill in the art.
  • the promoters used in the host cells of the invention may be modified, if desired, to affect their control characteristics.
  • the coding sequence used for overexpression of the enzymes mentioned above may preferably be homologous to the host cell of the invention. However, coding sequences that are heterologous to the host cell of the invention may be used.
  • Overexpression of an enzyme when referring to the production of the enzyme in a genetically modified host cell, means that the enzyme is produced at a higher level of specific enzymatic activity as compared to the unmodified host cell under identical conditions. Usually this means that the enzymatically active protein (or proteins in case of multi-subunit enzymes) is produced in greater amounts, or rather at a higher steady state level as compared to the unmodified host cell under identical conditions.
  • the mRNA coding for the enzymatically active protein is produced in greater amounts, or again rather at a higher steady state level as compared to the unmodified host cell under identical conditions.
  • Overexpression of an enzyme is thus preferably determined by measuring the level of the enzyme's specific activity in the host cell using appropriate enzyme assays as described herein.
  • overexpression of the enzyme may be determined indirectly by quantifying the specific steady state level of enzyme protein, e.g. using antibodies specific for the enzyme, or by quantifying the specific steady level of the mRNA coding for the enzyme.
  • the latter may particularly be suitable for enzymes of the pentose phosphate pathway for which enzymatic assays are not easily feasible as substrates for the enzymes are not commercially available.
  • an enzyme to be overexpressed is overexpressed by at least a factor of about 1.1 , about 1.2, about 1.5, about 2, about 5, about 10 or about 20 as compared to a strain which is genetically identical except for the genetic modification causing the overexpression.
  • these levels of overexpression may apply to the steady state level of the enzyme's activity, the steady state level of the enzyme's protein as well as to the steady state level of the transcript coding for the enzyme.
  • a cell of the invention may comprise one or more genetic modifications that increase the specific xylulose kinase activity.
  • the genetic modification or modifications causes overexpression of a xylulose kinase, e.g.
  • a nucleotide sequence used for overexpression of xylulose kinase in the host cell of the invention is a nucleotide sequence encoding a polypeptide with xylulose kinase activity.
  • the enzyme is also known as a phosphorylating xylulokinase, D-xylulokinase or ATP :D- xylulose 5- phosphotransferase.
  • a xylulose kinase of the invention may be further defined by its amino acid sequence.
  • a xylulose kinase may be defined by a nucleotide sequence encoding the enzyme as well as by a nucleotide sequence hybridising to a reference nucleotide sequence encoding a xylulose kinase.
  • a genetic modification or modifications that increase(s) the specific xylulose kinase activity may be combined with any of the modifications increasing the flux of the pentose phosphate pathway as described above. This is not, however, essential.
  • a host cell of the invention may comprise only a genetic modification or modifications that increase the specific xylulose kinase activity.
  • a xylulose kinase to be overexpressed is overexpressed by at least a factor of about 1.1 , about 1.2, about 1.5, about 2, about 5, about 10 or about 20 as compared to a strain which is genetically identical except for the genetic modification(s) causing the overexpression. It is to be understood that these levels of overexpression may apply to the steady state level of the enzyme's activity, the steady state level of the enzyme's protein as well as to the steady state level of the transcript coding for the enzyme.
  • a cell of the invention may comprise one or more genetic modifications that reduce unspecific aldose reductase activity in the host cell.
  • unspecific aldose reductase activity is reduced in the host cell by one or more genetic modifications that reduce the expression of or inactivates a gene encoding an unspecific aldose reductase.
  • the genetic modification(s) reduce or inactivate the expression of each endogenous copy of a gene encoding an unspecific aldose reductase in the host cell.
  • Host cells may comprise multiple copies of genes encoding unspecific aldose reductases as a result of di-, poly- or aneu-ploidy, and/or the host cell may contain several different (iso)enzymes with aldose reductase activity that differ in amino acid sequence and that are each encoded by a different gene. Also in such instances preferably the expression of each gene that encodes an unspecific aldose reductase is reduced or inactivated.
  • the gene is inactivated by deletion of at least part of the gene or by disruption of the gene, whereby in this context the term gene also includes any non-coding sequence up- or down-stream of the coding sequence, the (partial) deletion or inactivation of which results in a reduction of expression of unspecific aldose reductase activity in the host cell.
  • a nucleotide sequence encoding an aldose reductase whose activity is to be reduced in the host cell of the invention is a nucleotide sequence encoding a polypeptide with aldose reductase activity.
  • genetic modification that reduces unspecific aldose reductase activity in the host cell may be combined with any of the modifications increasing the flux of the pentose phosphate pathway and/or with any of the modifications increasing the specific xylulose kinase activity in the host cells as described above. This is not, however, essential.
  • a host cell of the invention comprising only a genetic modification or modifications that reduce(s) unspecific aldose reductase activity in the host cell is specifically included in the invention.
  • aldose reductase (EC 1.1.1.21 ) is herein defined as any enzyme that is capable of reducing xylose or xylulose to xylitol.
  • an aldose reductase may be any unspecific aldose reductase that is native (endogenous) to a host cell of the invention and that is capable of reducing xylose or xylulose to xylitol.
  • Unspecific aldose reductases catalyse the reaction: aldose + NAD(P)H + H + ⁇ alditol + NAD(P) +
  • the enzyme has a wide specificity and is also known as aldose reductase; polyol dehydrogenase (NADP + ); alditol:NADP oxidoreductase; alditol:NADP + 1- oxidoreductase; NADPH-aldopentose reductase; or NADPH-aldose reductase.
  • aldose reductase polyol dehydrogenase (NADP + ); alditol:NADP oxidoreductase; alditol:NADP + 1- oxidoreductase; NADPH-aldopentose reductase; or NADPH-aldose reductase.
  • a particular example of such an unspecific aldose reductase that is endogenous to S. cerevisiae and that is encoded by the GRE3 gene T raff et a/., 2001 , Appl. Environ. Micro
  • an aldose reductase of the invention may be further defined by its amino acid sequence.
  • an aldose reductase may be defined by the nucleotide sequences encoding the enzyme as well as by a nucleotide sequence hybridising to a reference nucleotide sequence encoding an aldose reductase.
  • a cell of the invention may be adapted to xylose utilisation by selection of mutants, either spontaneous or induced (e.g. by radiation or chemicals), for growth on xylose, preferably on xylose as sole carbon source, and more preferably under anaerobic conditions. Selection of mutants may be performed by techniques including serial passaging of cultures as e.g. described by Kuyper et al. (2004, FEMS Yeast Res. 4: 655-664) or by cultivation under selective pressure in a chemostat culture.
  • a preferred host cell of the invention at least one of the genetic modifications described above, including modifications obtained by selection of mutants, confer to the host cell the ability to grow on xylose as carbon source, preferably as sole carbon source, and preferably under anaerobic conditions.
  • the modified host cell produce essentially no xylitol, e.g. the xylitol produced is below the detection limit or e.g. less than about 5, about 2, about 1 , about 0.5, or about 0.3 % of the carbon consumed on a molar basis.
  • a cell of the invention may have the ability to grow on xylose as sole carbon source at a rate of at least about 0.05, about 0.1 , about 0.2, about 0.25 or about 0.3 h "1 under aerobic conditions, or, if applicable, at a rate of at least about 0.03, about 0.05, about 0.07, about 0.08, about 0.09, about 0.1 , about 0.12, about 0.15 or about 0.2 h "1 under anaerobic conditions.
  • the modified host cell has the ability to grow on a mixture of glucose and xylose (in a 1 :1 weight ratio) as sole carbon source at a rate of at least about 0.05, about 0.1 , about 0.2, about 0.25 or about 0.3 h "1 under aerobic conditions, or, if applicable, at a rate of at least about 0.03, about 0.05, about 0.1 , about 0.12, about 0.15, or about 0.2 h "1 under anaerobic conditions.
  • a cell of the invention may have a specific xylose consumption rate of at least about 200, about 250, about 300, about 346, about 350, about 400, about 500, about 600, about 750, or about 1000 mg xylose/g cells/h.
  • a cell of the invention may have a yield of fermentation product (such as ethanol) on xylose that is at least about 40, about 50, about 55, about 60, about 70, about 80, about 85, about 90, about 95 about 98 or about 99% of the host cell's yield of fermentation product (such as ethanol) on glucose. More preferably, the yield of a fermentation product (such as ethanol) of a cell of the invention on xylose may be equal to the cell's yield of fermentation product (such as ethanol) on glucose.
  • the cell's biomass yield on xylose may be at least about 40, about 50, about 55, about 60, about 70, about 80, about 85, about 90, about 95, about 98 or about 99% of the host cell's biomass yield on glucose. More preferably, the cell's biomass yield on xylose, may be equal to the host cell's biomass yield on glucose. It is understood that in the comparison of yields on glucose and xylose both yields are compared under aerobic conditions or both under anaerobic conditions.
  • a cell of the invention may be capable of using arabinose.
  • a cell of the invention may, therefore, be capable of converting L-arabinose into L-ribulose and/or xylulose 5- phosphate and/or into a desired fermentation product, for example one of those mentioned herein.
  • Organisms for example S. cerevisiae strains, able to produce ethanol from L- arabinose may be produced by modifying a cell introducing the araA (L-arabinose isomerase), araB (L-ribulokinase) and araD (L-ribulose-5-P4-epimerase) genes from a suitable source.
  • araA L-arabinose isomerase
  • araB L-ribulokinase
  • araD L-ribulose-5-P4-epimerase
  • a cell of the invention may be a cell suitable for the production of ethanol.
  • a cell of the invention may, however, be suitable for the production of fermentation products other than ethanol.
  • Such non-ethanolic fermentation products include in principle any bulk or fine chemical that is producible by a eukaryotic microorganism such as a yeast or a filamentous fungus.
  • Such fermentation products may be, for example, butanol, lactic acid, 3 - hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, itaconic acid, an amino acid, 1 ,3-propane-diol, ethylene, glycerol, a ⁇ - lactam antibiotic or a cephalosporin.
  • a preferred modified host cell of the invention for production of non-ethanolic fermentation products is a host cell that contains a genetic modification that results in decreased alcohol dehydrogenase activity.
  • the invention relates to fermentation processes in which the modified host cells of the invention are used for the fermentation of a carbon source comprising a source of xylose, such as xylose.
  • a carbon source comprising a source of xylose, such as xylose.
  • the carbon source in the fermentation medium may also comprise a source of glucose.
  • the source of xylose or glucose may be xylose or glucose as such or may be any carbohydrate oligo- or polymer comprising xylose or glucose units, such as e.g. lignocellulose, xylans, cellulose, starch and the like.
  • carbohydrases for release of xylose or glucose units from such carbohydrates, appropriate carbohydrases (such as xylanases, glucanases, amylases and the like) may be added to the fermentation medium or may be produced by the modified host cell. In the latter case the modified host cell may be genetically engineered to produce and excrete such carbohydrases.
  • An additional advantage of using oligo- or polymeric sources of glucose is that it enables to maintain a low(er) concentration of free glucose during the fermentation, e.g. by using rate- limiting amounts of the carbohydrases. This, in turn, will prevent repression of systems required for metabolism and transport of non-glucose sugars such as xylose.
  • the modified host cell ferments both the xylose and glucose, preferably simultaneously in which case preferably a modified host cell is used which is insensitive to glucose repression to prevent diauxic growth.
  • the fermentation medium will further comprise the appropriate ingredient required for growth of the modified host cell.
  • Compositions of fermentation media for growth of microorganisms such as yeasts are well known in the art.
  • the fermentation process is a process for the production of a fermentation product such as e.g.
  • ethanol butanol, lactic acid, 3 -hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, itaconic acid, an amino acid, 1 ,3-propane-diol, ethylene, glycerol, a ⁇ -lactam antibiotic, such as Penicillin G or Penicillin V and fermentative derivatives thereof, and a cephalosporin.
  • ⁇ -lactam antibiotic such as Penicillin G or Penicillin V and fermentative derivatives thereof, and a cephalosporin.
  • the fermentation process may be an aerobic or an anaerobic fermentation process.
  • An anaerobic fermentation process is herein defined as a fermentation process run in the absence of oxygen or in which substantially no oxygen is consumed, preferably less than about 5, about 2.5 or about 1 mmol/L/h, more preferably 0 mmol/L/h is consumed (i.e. oxygen consumption is not detectable), and wherein organic molecules serve as both electron donor and electron acceptors.
  • NADH produced in glycolysis and biomass formation cannot be oxidised by oxidative phosphorylation.
  • many microorganisms use pyruvate or one of its derivatives as an electron and hydrogen acceptor thereby regenerating NAD + .
  • pyruvate is used as an electron (and hydrogen acceptor) and is reduced to fermentation products such as ethanol, butanol, lactic acid, 3 -hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, an amino acid, 1 ,3-propane-diol, ethylene, glycerol, a ⁇ -lactam antibiotic and a cephalosporin.
  • the fermentation process is preferably run at a temperature that is optimal for the modified host cell.
  • the fermentation process is performed at a temperature which is less than about 42 0 C, preferably less than about 38 0 C.
  • the fermentation process is preferably performed at a temperature which is lower than about 35, about 33, about 30 or about 28 0 C and at a temperature which is higher than about 20, about 22, or about 25 0 C.
  • a preferred process is a process for the production of a ethanol, whereby the process comprises the steps of: (a) fermenting a medium containing a source of xylose with a modified host cell as defined above, whereby the host cell ferments xylose to ethanol; and optionally, (b) recovery of the ethanol.
  • the fermentation medium may also comprise a source of glucose that is also fermented to ethanol.
  • the volumetric ethanol productivity is preferably at least about 0.5, about 1.0, about 1.5, about 2.0, about 2.5, about 3.0, about 5.0 or about 10.0 g ethanol per litre per hour.
  • the ethanol yield on xylose and/or glucose in the process preferably is at least about 50, about 60, about 70, about 80, about 90, about 95 or about 98%.
  • the ethanol yield is herein defined as a percentage of the theoretical maximum yield.
  • the invention also relates to a process for producing a fermentation product, such as a product selected from the group consisting of butanol lactic acid, 3 -hydroxy- propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, itaconic acid, an amino acid, 1 ,3-propane-diol, ethylene, glycerol, a ⁇ -lactam antibiotic and a cephalosporin.
  • the process preferably comprises fermenting a medium containing a source of xylose with a modified host cell as defined herein above, whereby the host cell ferments xylose to the fermentation product.
  • the invention also provides a process for producing a fermentation product, such as a product selected from the group consisting of ethanol, butanol, lactic acid, 3- hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, itaconic acid, an amino acid, 1 ,3-propane-diol, ethylene, glycerol, a ⁇ - lactam antibiotic and a cephalosporin.
  • a fermentation product such as a product selected from the group consisting of ethanol, butanol, lactic acid, 3- hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, itaconic acid, an amino acid, 1 ,3-propane-diol, ethylene, glycerol, a ⁇ - lactam antibiotic and a cephalosporin.
  • the process preferably comprises fermenting a medium containing at least a source of xylose and a source of L-arabinose with a cell as defined above which is able to use both of xylose and L-arabinose such that the cell ferments xylose and L-arabinose to the fermentation product.
  • the invention also provides a process for producing a fermentation product, such as a product selected from the group consisting of ethanol, butanol, lactic acid, 3- hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, itaconic acid, an amino acid, 1 ,3-propane-diol, ethylene, glycerol, a ⁇ - lactam antibiotic and a cephalosporin.
  • a fermentation product such as a product selected from the group consisting of ethanol, butanol, lactic acid, 3- hydroxy-propionic acid, acrylic acid, acetic acid, succinic acid, citric acid, malic acid, fumaric acid, itaconic acid, an amino acid, 1 ,3-propane-diol, ethylene, glycerol, a ⁇ - lactam antibiotic and a cephalosporin.
  • the process preferably comprises fermenting a medium containing at least a source of xylose and a source of L-arabinose with a cell as defined above and a cell able to use L-arabinose, whereby each cell ferments xylose and/or arabinose to the fermentation product.
  • a process of the invention may also comprise recovery of the fermentation product.
  • the medium with which the process is carried out may also contain a source of glucose.
  • the process according to the present invention may be run under aerobic and anaerobic conditions.
  • the process is carried out under micro-aerophilic or oxygen limited conditions.
  • An anaerobic fermentation process is herein defined as a fermentation process run in the absence of oxygen or in which substantially no oxygen is consumed, preferably less than about 5, about 2.5 or about 1 mmol/L/h, and wherein organic molecules serve as both electron donor and electron acceptors.
  • An oxygen-limited fermentation process is a process in which the oxygen consumption is limited by the oxygen transfer from the gas to the liquid. The degree of oxygen limitation is determined by the amount and composition of the ingoing gasflow as well as the actual mixing/mass transfer properties of the fermentation equipment used.
  • the rate of oxygen consumption is at least about 5.5, more preferably at least about 6, such as at least 7 mmol/L/h.
  • Xylose isomerise activity (as determined in examples 1 and 2) Xylose isomerase activity may be assayed at 37 0 C in a reaction mixture containing 50 mM phosphate buffer (pH 7.0), 10 mM xylose, 10 mM MgCI 2 and a suitable amount of cell-free extract. The amount of xylulose formed may be determined by the cysteine-carbazole method (Goldstein and McCusker, Yeast 15, 1541-1553, 1999). Alternatively, xylose isomerase activity is assayed at 3O 0 C using the enzyme assay of Kersters-Hildersson et al.
  • Transformation of S. cerevisiae Transformation of S. cerevisiae was done as described by Gietz and Woods (2002; Transformation of the yeast by the LiAc/SS carrier DNA/PEG method. Methods in Enzymology 350: 87-96).
  • a single colony isolate was picked with a plastic toothpick and resuspended in 50 ⁇ l milliQ water. The sample was incubated for 10 minutes at 99°C. 5 ⁇ l of the incubated sample was used as a template for the PCR reaction, using Phusion® DNA polymerase (Finnzymes) according to the instructions provided by the supplier.
  • step 1 3' 98° C step 2 10" 98° C step 3 15" 58° C repeat step 2 to 4 for 30 cycles step 4 30" 72° C step 5 4' 72° C step 6 30" 20° C
  • 0.5 ml of 0.1 M MOPS buffer (pH 7.5) was added to the cell pellet of an overnight culture.
  • the cells were resuspended and transferred to a 2 ml Eppendorf tube which already contained 0.5 g of glassbeads with a diameter of 0.4-0.5 mm. All samples were vigorously shaked in an Eppendorf tube shaker (IKA VIBRAX-VXR) for 20 min at 4°C, at maximal speed.
  • the extract was centrifuged for 5 minutes at 14000 rpm and 4°C. The supernatant, which is the cell free extract, was transferred into a fresh Eppendorf tube.
  • xylose isomerase activity assay (general herein and in example 3)
  • the following method is a modified version of the method described by Dische- Borenfreud (J. Biol. Chem. (1951 ) 192, 2, 583-587).
  • One (1.0) ml of the substrate mix (100 mM MOPS pH 7.5, 10 mM MgCI 2 , 10 mM D-xylose) was mixed with 50 ⁇ l (diluted) cell free extract, in duplicate, on ice. Subsequently the reaction tubes were placed in a 50 0 C water bath for 30 minutes. In addition, the reactions were carried out at 30 0 C, also in duplicate. The reaction was stopped by placing the reaction tubes on ice water, followed by addition of 0.2 ml 1.67% L-cysteine monohydrate hydrochloride (Merck) solution.
  • Merck 0.2 ml 1.67% L-cysteine monohydrate hydrochloride
  • a series of dilutions was made ranging from approximately 2 to 20 ⁇ mole/ml. 50 ⁇ l of these fructose solutions were used in the assay as described above and the absorption at 560 nm was used to make a calibration curve. The activity of the samples was calculated by relating the absorbance at 560 nm to the calibration curve.
  • the protein concentration of the sample was determined according to a modified protocol of the Bradford method, using the Coomassie Plus Protein Assay (Thermo Scientific). The specific activity of xylose isomerase is expressed as nmol /mg protein. min.
  • Xylose isomerase [E. C. 4.2.1.2], GenBank accession number NC_000853 (SEQ ID NO: 1) from Thermotoga maritima MSB8 was analysed for the codon usage. The codon use was optimized as described in WO2006/077258 and WO2008/000632 (SEQ ID NO: 2).
  • the gene according to SEQ ID NO: 2 was cloned in front of the TP/7-promoter of S. cerevisiae. In order to prevent potential inefficient expression of the xylose isomerase, the following sequence was placed in front of the coding sequence: ACTAGTAAAAACACATACATAAACTAAAAATG . showing the start codon underlined.
  • a Spel restriction site ACTAGT was introduced in the strong, constitutive TPH- promoter, changing the sequence TCTTGCTTAAATCTATAACTACAAAAAACACATACATAAACTAAAAATG
  • Transformation mixtures are plated on Yeast Carbon Base (YCB) w/o ammonium sulphate (Difco), 4OmM KPi (pH 6.8) and 5mM acetamide. Untransformed cells cannot grow on this medium.
  • YCB Yeast Carbon Base
  • 4OmM KPi pH 6.8
  • 5mM acetamide Untransformed cells cannot grow on this medium.
  • Transformants are characterized using PCR techniques and/or Southern blotting techniques.
  • Saccharomyces cerevisiae strains are grown on medium having the following composition: 0.67% (w/v) yeast nitrogen base and either glucose, galactose or xylose, or a combination of these substrates (see below).
  • agar plates the medium is supplemented with 2% (w/v) bacteriological agar.
  • Ethanol production Shake-flask cultivations were performed at 30 0 C in a synthetic medium (Verduyn et al., Yeast 8:501-517, 1992). The pH of the medium was adjusted to 6.0 with 2 M KOH prior to sterilisation. For solid synthetic medium, 1.5% of agar was added. Pre-cultures were prepared by inoculating 100 ml medium containing the appropriate sugar in a 500-ml shake flask with a frozen stock culture. After incubation at 30 0 C in an orbital shaker (200 rpm), this culture was used to inoculate either shake- flask cultures.
  • the synthetic medium for anaerobic cultivation was supplemented with 0.01 g 1-1 ergosterol and 0.42 g 1-1 Tween 80 dissolved in ethanol (Andreasen and Stier. J. Cell Physiol. 41_:23-36, 1 953; and Andreasen and Stier. J. Cell Physiol. 43:271- 281 , 1954).
  • Saccharomyces cerevisiae strain CEN.PK1 13-7D or the derivative constitutively expressing the PPP (see Example 1 ), transformed with pYISIT4-XKS1-xylA (Thma
  • CpO CpO
  • agar plates with 2% glucose as carbon source.
  • single colonies are used to inoculate liquid medium with 100 mM xylose, 100 mM glucose and 100 mM galactose as carbon sources, or combinations thereof.
  • Saccharomyces cerevisiae strain CEN.PK1 13-7D or the derivative constitutively expressing the PPP are grown on agar plates with 2% glucose as carbon source. When colonies were visible, single colonies are used to inoculate a synthetic medium (Verduyn et al., supra). Mixtures of glucose, xylose and or galactose are added to the medium as a carbon source, ranging from 0 to 50 grams per liter. Growth is monitored by measuring the increase in optical density at 600 nm on a LKB Ultrospec K spectrophotometer. Ethanol production and sugar consumption in time are monitored by HPLC and/or NMR analysis.
  • Saccharomyces cerevisiae BIE104P1 expressing the genes TAL1, TKL1, RKH and RPEI constitutively, was obtained by transforming CEN.PK113-7D [MATa URA3
  • Plasmid pPWTO ⁇ O HIS3 LEU2 TRP1 MAL2-8 SUC2 with plasmid pPWTO ⁇ O (figure 2).
  • plasmid pPWTO ⁇ O was constructed by using synthetic DNA, synthesized by GeneArt
  • plasmid pPWT080 consists of the promoter region of the GRE3-gene, followed by the four PPP-genes TAL1, TKL1, RKH and RPE1 under control of strong constitutive promoters, and the 3' non-coding sequences of the GRE3-gene, as set out in figure 2.
  • the kanMX-gene conferring resistance to G41 ⁇ and the Aspergillus amc/S-gene allowing the transformants to grow in acetamide as sole nitrogen source are present on this plasmid.
  • pPWTO ⁇ O Prior to the transformation of CEN.PK1 13-7D, pPWTO ⁇ O was linearized using the restriction enzyme Sfi ⁇ (New England Biolabs), according to the instructions provided by the supplier. Transformation mixtures were plated on YPD-agar (per liter:
  • yeast extract 10 grams of yeast extract, 20 grams per liter peptone, 20 grams per liter dextrose, 20 grams of agar) containing 100 ⁇ g G41 ⁇ (Sigma Aldrich) per ml.
  • plasmid pPWTO ⁇ O The integration of plasmid pPWTO ⁇ O is directed to the GRE3-locus. Transformants were characterized using PCR and Southern blotting techniques. PCR reactions, which are indicative for the correct integration of one copy of plasmid pPWTO ⁇ O, were performed with the primers indicated by SEQ ID 5 and 6, and 6 and 7 (see figure 3). With the primer pairs of SEQ ID 5 and 6, the correct integration at the GR£3-locus was checked. If plasmid pPWTO ⁇ O was integrated in multiple copies (head-to-tail integration), the primer pair of SEQ ID 6 and 7 will give a PCR-product. If the latter PCR product is absent, this is indicative for a one copy integration.
  • a Southern blot analysis was performed. To this end, the chromosomal DNA was isolated from the wild-type strain CEN.PK113-7D and transformants using standard molecular biology techniques. The chromosomal DNA was digested with the restriction enzymes Xcm ⁇ and Psi ⁇ , electroforesed over a 0.7% agarose gel and the DNA was transferred to a nylon membrane (Hybond N+, Amersham Pharmacia Biotech) according to the instructions of the manufacturer.
  • a probe for detecting the correct integration of the plasmid pPWTO ⁇ O a probe derived from the RKH-qene, present in plasmid pPWT080, was used.
  • the probe was made by using the primers of SEQ ID 9 and 10 and plasmid pPWTO ⁇ O as a template.
  • the labeling of the probe and the subsequent hybridization and washing procedures were performed as suggested by the supplier of the ECL Direct Labeling and Detection System (GE Life Sciences).
  • the autoradiogram shows correct integration of one copy of plasmid pPWTO ⁇ O, in accordance with the expected hybridisation pattern as can be deduced from figure 3 (panel c).
  • the strain was designated BIE104F1.
  • plasmid pPWTO ⁇ O In order to be able to introduce the genes encoding xylose isomerase and xylulokinase (section 3.2), it is necessary to remove the selection markers introduced by the integration of plasmid pPWTO ⁇ O.
  • the design of plasmid pPWTO ⁇ O was such, that upon integration of pPWTO ⁇ O in the chromosome, homologous sequences are in close proximity of each other. This design allows the selectable markers to be lost by spontaneous intramolecular recombination of these homologous regions.
  • the promoter region of the Gf?£3-gene and the 3' non-coding region of the GRE3-gene are duplicated after integration of one copy of pPWTO ⁇ O at the GRE3- locus of S. cerevisiae.
  • intramolecular recombination will take place, although at low frequency. The frequency of this recombination depends on the length of the homology and the locus in the genome (unpublished results).
  • intramolecular recombinants Upon sequential transfer of a subfraction of the culture to fresh medium, intramolecular recombinants will accumulate in time.
  • strain BIE104F1 was cultured in YPD-medium (per liter: 10 grams of yeast extract, 20 grams per liter peptone, 20 grams per liter dextrose), starting from a colony isolate. 25 ⁇ l of an overnight culture was used to inoculate fresh YPD-medium. After five serial transfers, the optical density of the culture was determined and cells were diluted to a concentration of approximately 5000 per ml. 100 ⁇ l of the cell suspension was plated on Yeast Carbon Base medium (Difco) containing 30 mM KPi (pH 6.8), 0.1% (NhU) 2 SO 4 , 40 mM fluoro-acetamide (Amersham) and 1.8% agar (Difco).
  • YPD-medium per liter: 10 grams of yeast extract, 20 grams per liter peptone, 20 grams per liter dextrose
  • 25 ⁇ l of an overnight culture was used to inoculate fresh YPD-medium. After five serial transfers, the optical density
  • primers of SEQ ID 5 and 6 do not result in a PCR product, recombination has taken place, but in such a way that the complete plasmid pPWT080 has recombined out of the genome. Not only were the selectable markers lost, but also the four PPP- genes. In fact, wild-type yeast has been retrieved.
  • Plasmid pYISIT4-XKS1-xylA (Thma CpO), as set out in figure 1 , was improved in order to allow for G418 selection of the transformants.
  • a 4648 bp insert containing the xylA-gene under control of the TP/7-promoter and the XKS1-gene under control of the TD/-/7-promoter was excised from plasmid pYISIT4-XKS1-xylA (Thma CpO) (figure 1 ), using the restriction enzymes MuI and Sacll.
  • Plasmid pYI#SIT4 as set out in figure 6, was digested with restriction enzyme Acc65 ⁇ .
  • kanamycin-resistance marker present on plasmid p427TEF (Dualsystems Biotech AG), allowing selection in E. coli (kanamycin) and S. cerevisiae (G418) was isolated by PCR using primers of SEQ ID 1 1 and 12.
  • the sequence of primer of SEQ ID 12 was designed in such a way that the Mul-site in the kanMX- fragment was lost, which keeps the Mul-site in the resulting plasmid (pPWT007, see below) unique.
  • the PCR product was subcloned in the pCRII-TOPO vector using the Zero Blunt® TOPO PCR Cloning Kit for Sub-cloning (Invitrogen).
  • Plasmid pPWT007 was cleaved with the restriction enzymes MuI and Sacll. After clean-up of this vector, the above described 4648 bp Mul-Sacll fragment of pYISIT4-XKS1-xylA (Thma CpO) was ligated. The resulting plasmid is called pPWT049, which is set out in figure 8.
  • PCR reactions using Phusion® DNA polymerase (Finnzymes), which are indicative for the correct integration of one copy of plasmid pPWT049, were performed with the primers indicated by SEQ IDs 13 and 14, and 14 and 15.
  • the correct integration at the S/74-locus was checked.
  • the correct integration of the plasmid in the S/74-locus may also be checked with primer pair SEQ ID 15 and 16 (figure 9). If plasmid pPWT049 was integrated in multiple copies (head-to-tail integration), the primer pair of SEQ ID 14 and 15 will give a PCR-product. If the latter PCR product is absent, this is indicative for one copy integration of plasmid pPWT049
  • a strain with one copy of plasmid pPWT049 integrated into the genome was designated BIE104P1Y16.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

L'invention concerne une cellule qui comprend une séquence nucléotidique codant une xylose isomérase, la séquence d'acides aminés de la xylose isomérase présentant environ au moins 70% d'identité séquentielle par rapport à la séquence d'acides aminés définie dans SEQ ID NO: 3, ladite séquence nucléotidique étant hétérologue à celle de l'hôte. Une cellule selon l'invention peut être utilisée dans un procédé pour produire un produit de fermentation comme l'éthanol. Un tel procédé peut consister à faire fermenter un milieu contenant une source de xylose à l'aide d'une cellule selon l'invention, de sorte que ladite cellule fasse fermenter la xylose pour obtenir un produit de fermentation selon l'invention.
PCT/EP2009/052621 2008-03-07 2009-03-05 Cellule de fermentation de sucre pentose WO2009109631A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08102411.9 2008-03-07
EP08102411 2008-03-07

Publications (2)

Publication Number Publication Date
WO2009109631A1 WO2009109631A1 (fr) 2009-09-11
WO2009109631A9 true WO2009109631A9 (fr) 2009-11-05

Family

ID=40756316

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2009/052621 WO2009109631A1 (fr) 2008-03-07 2009-03-05 Cellule de fermentation de sucre pentose

Country Status (1)

Country Link
WO (1) WO2009109631A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102803649A (zh) 2009-06-25 2012-11-28 国际壳牌研究有限公司 注水系统和方法
EP2451960A2 (fr) 2009-07-09 2012-05-16 Verdezyne, Inc. Micro-organismes modifiés ayant une activité de fermentation améliorée
WO2011131667A1 (fr) 2010-04-21 2011-10-27 Dsm Ip Assets B.V. Cellule adaptée pour la fermentation d'une composition de sucre mélangé
US8889384B2 (en) 2010-10-07 2014-11-18 Shell Oil Company Process for the production of alcohols from biomass
CN103189526B (zh) 2010-11-05 2015-07-08 国际壳牌研究有限公司 处理生物质以产生可用于生物燃料的材料
US8609379B2 (en) 2010-12-20 2013-12-17 Shell Oil Company Process for the production of alcohols from biomass
AR086471A1 (es) * 2011-04-22 2013-12-18 Dsm Ip Assets Bv Celula de levadura capaz de convertir azucares que incluyen arabinosa y xilosa
PL2791344T3 (pl) 2011-12-15 2016-08-31 Shell Int Research Sposób obróbki produktów ubocznych z wytwarzania etanolu
WO2013169706A1 (fr) 2012-05-07 2013-11-14 Shell Oil Company Procédé continu ou semi-continu de traitement d'une biomasse pour obtenir des matériaux utiles pour les biocarburants
IN2014DN09550A (fr) 2012-05-17 2015-07-17 Shell Int Research
JP6249391B2 (ja) * 2012-06-15 2017-12-20 国立研究開発法人農業・食品産業技術総合研究機構 キシロースを高温で発酵する方法
CN106232826A (zh) 2014-04-17 2016-12-14 国际壳牌研究有限公司 生产发酵产品的方法
CN106573884B (zh) 2014-08-14 2018-09-28 国际壳牌研究有限公司 处理生物质以生产用于生物燃料的物质的改进方法
EP3180321A4 (fr) 2014-08-14 2018-04-11 Shell International Research Maatschappij B.V. Procédé de préparation de furfural à partir d'une biomasse
CA2954306C (fr) 2014-08-14 2022-08-30 Shell Internationale Research Maatschappij B.V. Procede permettant de preparer du furfural a partir d'une biomasse
CN107849514A (zh) 2015-07-13 2018-03-27 玛拉可再生能源公司 增强木糖的微藻代谢
AU2016301365A1 (en) 2015-08-05 2018-03-08 Cargill, Incorporated Xylose isomerase-modified yeast strains and methods for bioproduct production
CN109071478A (zh) 2016-05-03 2018-12-21 国际壳牌研究有限公司 木质素基溶剂和其制备方法
WO2018085176A1 (fr) 2016-11-01 2018-05-11 Shell Oil Company Procédé de récupération de furfural
US10899725B2 (en) 2016-11-01 2021-01-26 Shell Oil Company Process for the recovery of furfural
CA3039790A1 (fr) 2016-11-01 2018-05-11 Shell Internationale Research Maatschappij B.V. Procede de recuperation de furfural
US10501430B2 (en) 2016-11-01 2019-12-10 Shell Oil Company Process for the recovery of furfural
WO2020234303A1 (fr) 2019-05-22 2020-11-26 Shell Internationale Research Maatschappij B.V. Procédé de production de furfural
WO2024158616A1 (fr) 2023-01-23 2024-08-02 Shell Usa, Inc. Procédé de traitement de grains pour produire un matériau utile pour des produits chimiques et des biocarburants

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656497A (en) * 1994-09-06 1997-08-12 Michigan State University Gene encoding hyperthermostable xylose isomerase from Thermotoga neapolitana
US5935837A (en) * 1997-07-28 1999-08-10 Novo Nordisk A/S DNA constructs and methods of producing xylose isomerase
CN1702172B (zh) * 2004-05-26 2011-12-07 百瑞全球有限公司 葡萄糖异构酶突变体
CN101052706B (zh) * 2004-07-16 2015-02-18 帝斯曼知识产权资产管理有限公司 发酵木糖的真核细胞的代谢工程

Also Published As

Publication number Publication date
WO2009109631A1 (fr) 2009-09-11

Similar Documents

Publication Publication Date Title
US8399215B2 (en) Pentose sugar fermenting cell
US10982235B2 (en) Fermentative production of ethanol from glucose, galactose and arabinose employing a recombinant yeast strain
WO2009109631A1 (fr) Cellule de fermentation de sucre pentose
EP1468093B1 (fr) Fermentation de sucres pentose
US20110189728A1 (en) Pentose sugar fermenting cell
US10100320B2 (en) Pentose sugar fermenting cell
WO2009109630A1 (fr) Cellule de fermentation de sucre pentose
EP2554668A1 (fr) Cellule de fermentation de sucre de pentose

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09716866

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09716866

Country of ref document: EP

Kind code of ref document: A1